CD274 and esophageal squamous cell carcinoma: Lately, a phase 1b trial using adebrelimab showed a pathological complete response (pCR) rate of 8% and 2-year OS of 92%, suggesting neoadjuvant anti-PD-L1 monotherapy as a therapeutic strategy for patients with resectable ESCC [6].